|Videos|July 18, 2014
Return of Interferon in RCC
Advertisement
Episodes in this series
For High-Definition, Click
Although not commonly used, interferon could soon be undergoing a renaissance for patients with renal cell carcinoma (RCC), believes Nicholas J. Vogelzang, MD. This treatment is still commonly used in Japan and will soon be combined with PD-1 inhibitors in clinical trials. It seems likely that interferon will once again have a role for patients with RCC, Vogelzang suggests.
Advertisement
Related to this article
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Poll Results Highlight Breast Cancer Abstracts of Interest at ESMO 2026
3
FDA Grants Fast Track Designation to Opamtistomig for Advanced Biliary Tract Cancer
4
Dr Hansen on the Integration of CAR T-Cell Therapy Into Earlier Myeloma Treatment Lines
5